Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical application of (E)-3-aromatic heterocyclic propyl-2-olefine acid derivative

A pharmacy, alkyl technology, applied in the field of pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives, can solve any problems such as

Active Publication Date: 2021-07-23
MEDCURIUS INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases. Currently, there is no drug that can cure AD and PD, or even delay the progress of AD and PD. Some drugs for the treatment of AD and PD can only improve the symptoms of AD and PD patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of (E)-3-aromatic heterocyclic propyl-2-olefine acid derivative
  • Pharmaceutical application of (E)-3-aromatic heterocyclic propyl-2-olefine acid derivative
  • Pharmaceutical application of (E)-3-aromatic heterocyclic propyl-2-olefine acid derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062]

[0063] Steps: 0.298 g (2 mmol) pyridin-2-acrylic acid (compound a) and 10 ml of methanol in the reaction flask, slowly added 0.03 g (0.3 mmol) concentrated sulfuric acid, and the room temperature was reacted for 3 hours, and saturated saturated carbonated. The hydrogen sodium hydrogen solution regulates about 8, then extracted with dichloromethane, dried off anhydrous sulfate, filtered, concentrated, dried, 0.223 g of compound I-1, yield: 68%. 1 H NMR (CDCL 3 : Δ3.82 (S, 3H), 6.95 (D, 1H, J = 16.0 Hz), 7.28 (m, 1H), 7.43 (D, 1H, J = 8.0 Hz), 7.70 (D, 1H, J = 16.0Hz), 7.73 (m, 1H), 8.66 (D, 1H, J = 4.0 Hz); MS (ESI): M / Z 164 [M + H] + .

Embodiment 2

[0065]

[0066]Steps: 0.298 g (2 mmol) pyridine-2-acrylic acid (Compound A) and 10 ml of ethanol, slowly added 0.03 g (0.3 mmol) concentrated sulfuric acid, and saturated saturated carbonated at room temperature. The hydrogen sodium hydrogen solution is adjusted to be about 8, then extracted with dichloromethane, dried off anhydrous sulfate, filtered, concentrated, dried to give 0.249 grams of compound I-2, yield: 72%. 1 H NMR (CDCL 3 : Δ1.34 (T, 3H, J = 8.0 Hz), 4.28 (Q, 2H, J = 8.0 Hz), 6.93 (D, 1H, J = 16.0 Hz), 7.28 (M, 1H), 7.44 (D 1H, J = 8.0 Hz), 7.69 (D, 1H, J = 16.0 Hz), 7.73 (m, 1H), 8.66 (D, 1H, J = 4.0 Hz); MS (ESI): M / Z 178 [ M + h] + .

Embodiment 3

[0068]

[0069] Steps: 0.298 g (2 mmol) pyridine-3-acrylic acid (Compound A) and 10 ml of methanol in the reaction bottle, slowly drop 0.03 g (0.3 mmol) concentrated sulfuric acid, room temperature for 3 hours, drop saturated carbonated The hydrogen sodium hydrogen solution is adjusted to be about 8, then extracted with dichloromethane, dried with no water sulfate, filtrate, concentrated, dried, 0.233 g of compound I-3, yield: 71%. 1 H NMR (CDCL 3 : Δ3.75 (S, 3H), 6.44 (D, 1H, J = 16.0 Hz), 7.27 (DD, 1H, J = 4.0, 8.0 Hz), 7.61 (D, 1H, J = 16.0 Hz), 7.77 (D, 1H, J = 8.0 Hz), 8.54 (D, 1H, J = 4.0 Hz), 8.67 (S, 1H); MS (ESI): M / Z 164 [M + H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical application of (E)-3-aromatic heterocyclic propyl-2-olefine acid derivatives. The compound is a novel Nrf2 activator, and has the effects of resisting oxidative stress, resisting neuritis and enhancing mitochondrial function and biogenesis by effectively activating an Nrf2 signal channel, so that nerve cells are protected, and the compound can be used for treating neurodegenerative diseases and cerebral apoplexy. In addition, such novel Nrf2 activators can also be used for the treatment of autoimmune diseases, diabetes and nephropathy as well as other chronic diseases.

Description

Technical field [0001] The present application relates to a new type of NRF2 activator, which produces anti-oxidation stress, antioxmonitis, and enhanced mitochondrial function and biological occurrence by effectively activating NRF2 signaling pathways, thereby protecting nerve cells, so it can be used In the treatment of multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson Disease (PD), Huntington (HD), Myocytreatry (ALS), Friedry Complementary disorders (FRDA), spinal cord muscle atrophy (SMA), optic nerve spinalin (NMO) and spinal cortex (SCA) and other neurodegenerative diseases can also be used to treat stroke. In addition, such new NRF2 activators can also be used to treat autoimmune diseases, diabetes and nephropathy, and other chronic diseases. The present application also relates to the preparation of such compounds. Background technique [0002] Neurodegenerative disease is a disease that is still unable to cure, which causes nerve cells to perform sexual degene...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D213/55C07D213/56C07D213/57A61K31/4402A61K31/4406A61K31/4409A61P25/28A61P25/14A61P25/16A61P21/00A61P9/00A61P11/00A61P3/10A61P13/12A61P9/10A61P9/12A61P9/04A61P11/06A61P19/02A61P17/06A61P29/00A61P27/02A61P37/06A61P5/14A61P37/02
CPCC07D213/55C07D213/56C07D213/57A61P25/28A61P25/14A61P25/16A61P21/00A61P9/00A61P11/00A61P3/10A61P13/12A61P9/10A61P9/12A61P9/04A61P11/06A61P19/02A61P17/06A61P29/00A61P27/02A61P37/06A61P5/14A61P37/02A61K31/505A61K31/426A61K31/421A61K31/4402A61K31/4164A61K31/4409A61K31/4439A61K9/0019
Inventor 赵旭阳文军
Owner MEDCURIUS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com